NDAOTICINJECTABLE, SUSPENSION
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
OTIPRIO (ciprofloxacin) by Hikma is [see ] . Approved for urinary tract infection, acute pyelonephritis, anthrax and 1 more indications. First approved in 2015.
Drug data last refreshed 19h ago
Mechanism of Action
[see ] . Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.
Indications (4)
Worked on OTIPRIO at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.